Published in Neuropharmacology on February 05, 2009
D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia. Neurology (2015) 1.38
L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission. Front Behav Neurosci (2011) 1.30
PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol (2010) 1.13
Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation. Front Neuroanat (2011) 1.01
The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addict Biol (2010) 0.98
Cocaine self-administration in dopamine D₃ receptor knockout mice. Exp Clin Psychopharmacol (2012) 0.90
Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. Nucl Med Biol (2011) 0.88
Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands. J Med Chem (2011) 0.85
Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. Eur Neuropsychopharmacol (2014) 0.80
Dopamine D3 receptors regulate reconsolidation of cocaine memory. Neuroscience (2013) 0.79
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. Eur J Neurosci (2012) 0.79
Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. J Pharmacol Exp Ther (2010) 0.79
Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats. Neuropharmacology (2010) 0.78
Dopamine D1 and D3 receptors mediate reconsolidation of cocaine memories in mouse models of drug self-administration. Neuroscience (2014) 0.78
Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand. J Neurochem (2014) 0.77
Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum. Basal Ganglia (2012) 0.76
Synthesis and in vitro pharmacological evaluation of indolyl carboxylic amide analogues as D3 dopamine receptor selective ligands. Medchemcomm (2013) 0.75
CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology (2000) 5.63
Aromatic amino acids and modification of parkinsonism. N Engl J Med (1967) 5.46
6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol (1968) 2.81
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain (2007) 2.49
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci (1998) 2.10
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci (2002) 2.01
Levodopa-induced dyskinesias. Mov Disord (2007) 1.94
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) (2007) 1.94
Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol (2002) 1.90
Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther (2005) 1.87
Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem (2005) 1.77
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med (2003) 1.73
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci (2007) 1.61
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci (2001) 1.57
Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharm Des (2003) 1.40
Food restriction alters N'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. J Pharmacol Exp Ther (2008) 1.31
Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A (1997) 1.28
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res (2007) 1.28
Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem (2005) 1.26
Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol (2008) 1.24
Characterization of (125)I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Synapse (2000) 1.19
D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res (1998) 1.17
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem (2006) 1.17
Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord (2005) 1.13
Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord (2001) 1.10
Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci (2000) 1.08
Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol (1999) 1.07
WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl) (2006) 1.07
In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias. Neurobiol Dis (2007) 1.04
Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence. Brain Res Brain Res Rev (1998) 1.01
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis (2003) 1.01
Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology (2007) 0.99
6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol Ther B (1976) 0.97
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem (2003) 0.96
Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord (2003) 0.92
High-frequency stimulation of the subthalamic nucleus reverses limb-use asymmetry in rats with unilateral 6-hydroxydopamine lesions. Brain Res (2004) 0.91
Drug therapy for Parkinson's disease. Semin Neurol (2007) 0.88
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol (2000) 0.87
Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther (2004) 0.87
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci (1989) 0.84
WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. Eur J Pharmacol (2007) 0.84
D1/D3 receptor relationships in brain coexpression, coactivation, and coregulation. Adv Pharmacol (1998) 0.83
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse (2008) 0.83
A retrospect on the discovery of WAY-100635 and the prospect for improved 5-HT(1A) receptor PET radioligands. Nucl Med Biol (2000) 0.82
Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol (2000) 0.81
Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci (1996) 0.78
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2010) 5.86
The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci (2008) 2.72
Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol (2007) 2.64
RGS9 modulates dopamine signaling in the basal ganglia. Neuron (2003) 2.61
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) (2007) 1.94
Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J Med Chem (2012) 1.87
Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther (2005) 1.87
Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem (2005) 1.77
Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem (2005) 1.74
The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology (2005) 1.69
Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2007) 1.54
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem (2009) 1.52
Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci (2005) 1.49
Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J Pharmacol Exp Ther (2004) 1.44
Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse (2005) 1.43
Food restriction alters N'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. J Pharmacol Exp Ther (2008) 1.31
Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs. J Neurosci (2009) 1.26
Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem (2005) 1.26
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol (2007) 1.20
N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. J Med Chem (2011) 1.20
Postendocytic sorting of constitutively internalized dopamine transporter in cell lines and dopaminergic neurons. J Biol Chem (2010) 1.17
Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther (2005) 1.14
Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity. J Pharmacol Exp Ther (2009) 1.13
PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol (2010) 1.13
N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists. Bioorg Med Chem Lett (2003) 1.12
R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry (2012) 1.12
The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology (2010) 1.11
Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J Pharmacol Exp Ther (2010) 1.09
Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric binding of antidepressants to the serotonin transporter. J Biol Chem (2012) 1.09
Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter. J Med Chem (2005) 1.07
BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. Eur J Pharmacol (2005) 1.07
Effects of selective dopaminergic compounds on a delay-discounting task. Behav Pharmacol (2011) 1.06
Synthesis and characterization of selective dopamine D2 receptor antagonists. Bioorg Med Chem (2005) 1.06
[(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization. Synapse (2009) 1.05
Quantitative changes in Galphaolf protein levels, but not D1 receptor, alter specifically acute responses to psychostimulants. Neuropsychopharmacology (2006) 1.04
Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR. Bioorg Med Chem Lett (2006) 1.04
Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2007) 1.04
Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. Bioorg Med Chem Lett (2004) 1.03
Labeling of dopamine transporter transmembrane domain 1 with the tropane ligand N-[4-(4-azido-3-[125I]iodophenyl)butyl]-2beta-carbomethoxy-3beta-(4-chlorophenyl)tropane implicates proximity of cocaine and substrate active sites. Mol Pharmacol (2008) 1.03
The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology (Berl) (2013) 1.02
N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects. J Pharmacol Exp Ther (2010) 1.01
Assessment of the influence of histaminergic actions on cocaine-like effects of 3alpha-diphenylmethoxytropane analogs. J Pharmacol Exp Ther (2005) 1.00
Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J Pharmacol Exp Ther (2003) 1.00
Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. Antimicrob Agents Chemother (2008) 0.99
D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem (2004) 0.98
Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology (2009) 0.97
Behavioral effects of rimcazole analogues alone and in combination with cocaine. Eur J Pharmacol (2003) 0.97
Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther (2009) 0.96
Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect? Mov Disord (2010) 0.96
Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2006) 0.96
Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods. J Chem Inf Model (2010) 0.95
Single molecule analysis reveals coexistence of stable serotonin transporter monomers and oligomers in the live cell plasma membrane. J Biol Chem (2014) 0.94
Place conditioning and locomotor effects of N-substituted, 4',4''-difluorobenztropine analogs in rats. J Pharmacol Exp Ther (2005) 0.94
Probing binding pocket of serotonin transporter by single molecular force spectroscopy on living cells. J Biol Chem (2011) 0.94
Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44. Pharmacol Biochem Behav (2009) 0.93
The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors. Mol Pharmacol (2010) 0.93
Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study. Synapse (2011) 0.92
A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors. Mol Pharmacol (2013) 0.92
Yawning and locomotor behavior induced by dopamine receptor agonists in mice and rats. Behav Pharmacol (2010) 0.92
Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues. ACS Med Chem Lett (2010) 0.91
The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol Biochem Behav (2007) 0.90
Cocaine self-administration in dopamine D₃ receptor knockout mice. Exp Clin Psychopharmacol (2012) 0.90
Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways. Synapse (2010) 0.89
Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists. Psychopharmacology (Berl) (2010) 0.89
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents. J Med Chem (2003) 0.89
Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D₃ receptor antagonists. J Med Chem (2014) 0.88
The discriminative stimulus effects of dopamine D2- and D3-preferring agonists in rats. Psychopharmacology (Berl) (2008) 0.88
Synthesis and in vitro biological evaluation of carbonyl group-containing analogues for σ1 receptors. J Med Chem (2011) 0.88
Structure-activity relationship comparison of (S)-2beta-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes and (R)-2beta-substituted 3beta-(3,4-dichlorophenyl)tropanes at the dopamine transporter. J Med Chem (2003) 0.88
Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. Nucl Med Biol (2011) 0.88
Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters. J Med Chem (2010) 0.87
Radioiodinated azide and isothiocyanate derivatives of cocaine for irreversible labeling of dopamine transporters: synthesis and covalent binding studies. Bioconjug Chem (2005) 0.87
Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorg Med Chem (2010) 0.87
Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands. J Med Chem (2011) 0.85